HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Higher pretherapy and significant decrease during the first 12 months of therapy in serum laminin levels may associate with hepatitis B e antigen seroconversion in chronic hepatitis B patients treated with lamivudine.

Abstract
Laminin participates in regulating immune response in addition to being a biomarker of liver fibrosis. Lamivudine has been shown to be able to restore cytotoxic T-cell response in chronic hepatitis B. In this study, fifty-two patients with HBeAg-positive chronic hepatitis B received lamivudine treatment for more than 12 months. Serum laminin levels were determined at baseline and during treatment and analyzed regarding treatment responses at the end of 12 months of therapy. The results showed that laminin levels at 12 months of treatment in patients who lost HBeAg were significantly lower compared with baseline (P = 0.001). The baseline laminin levels were higher in HBeAg seroconversion group than those without seroconversion (P = 0.037). Compared with baseline, the levels of serum laminin in HBeAg seroconversion group showed significant decrease (P = 0.001). It is concluded that higher pretherapy and significant decrease during the first 12 months of therapy in laminin levels may associate with HBeAg seroconversion in chronic hepatitis B patients treated with lamivudine, indicating the possible novel information of laminin for clinical reference.
AuthorsQunying Han, Sai Lou, Zhengwen Liu, Ni Zhang, Guoyu Zhang, Yi Lv, Shaoqiong Duan, Zhu Li
JournalClinical and experimental medicine (Clin Exp Med) Vol. 10 Issue 4 Pg. 245-51 (Dec 2010) ISSN: 1591-9528 [Electronic] Italy
PMID20135338 (Publication Type: Journal Article)
Chemical References
  • Antiviral Agents
  • Biomarkers
  • Hepatitis B e Antigens
  • Laminin
  • Lamivudine
Topics
  • Adult
  • Antiviral Agents (therapeutic use)
  • Biomarkers (blood)
  • Female
  • Hepatitis B e Antigens (blood)
  • Hepatitis B, Chronic (drug therapy)
  • Humans
  • Laminin (blood)
  • Lamivudine (therapeutic use)
  • Male
  • Prognosis
  • Serum (chemistry)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: